Effect of Aprotinin and Recombinant Variants on Platelet Protease-Activated Receptor 1 Activation

Aprotinin variants differentially inhibit PAR1-mediated platelet aggregation. With more understanding of the mechanisms of action of aprotinin and its derivatives, safer and more efficacious aprotinin variants may become available for clinical use.